Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study

Mattiolli, Aline; Santos, Allan O.; Vicente, Andreia; Queiroz, Marcelo A.; Bastos, Diogo Assed; Herchenhorn, Daniel; Srougi, Miguel; Peixoto, Fábio A; Morikawa, L.K.; Silva, João Luiz Fernandes da; Etchebehere, Elba

doi:10.1590/s1677-5538.ibju.2017.0632

Cited by 23 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultimately 16 studies were included in the review (Tab. 2; [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]). Twelve studies reported outcomes using [ 68 Ga]-PSMA-11 PET, while four studies reported data on other PSMA-tracers.…”

Section: Resultsmentioning

confidence: 99%

“…Afaq et al found that higher PSA levels were significantly (p = 0.024) associated with management changes; 25.0%, 26.3%, 33.3%, 50.0%, 38.5%, and 50.0% for PSA values <0.2, 0.2-<0.5, 0.5-<1.0, 1.0 < 2.0, 2.0-<5.0, and ≥5.0 ng/ml respectively [38]. Mattiolli et al also found a predictive value of higher PSA levels for change of management (p < 0.0001) [30]. In contrast to these findings, Calais et al found no association between change of management and PSA levels at [ 68 Ga]-PSMA-11 PET/CT [26].…”

Section: Discussionmentioning

confidence: 95%

“…Matiollo et al evaluated the clinical impact of [ 68 Ga]-PSMA PET/CT and correlated potential treatment changes to age, Gleason score, PSA level and SUVmax [30]. A change in treatment was found in 66/104 patients.…”

Section: Houten 2020mentioning

confidence: 99%

See 2 more Smart Citations

Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature

et al. 2020

View full text Add to dashboard Cite

PSMA PET is increasingly used for localising biochemical recurrent prostate cancer (BCR) and is incorporated in European and national guidelines. Nevertheless, clinical implications of PSMA PET need to be clarified. In this report, the available literature on the clinical impact of PSMA PET in patients with BCR is reviewed. A comprehensive literature search was performed using the MEDLINE® database. All studies reporting data on PSMA PET directed patient management were considered relevant. In the review, 16 studies were included. Change of management was 45% for the pooled data (861/1899 patients), of which 50% changed from non-targeted to targeted approach. Change from targeted to non-targeted approaches was found in 17% of patients. High heterogeneity was found between presently available studies. It can be concluded that PSMA PET induces change of management in almost half of the patients with BCR. After PSMA PET more patients are selected for metastasis targeted therapies. Potential beneficial effects of metastasis directed therapies require further evaluation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, do clinical decisions change in patients with oligometastatic disease seen in PSMA PET/CT? Table 2 summarizes the results of six retrospective and three prospective studies that observed changes in the management of recurrent PCa following PSMA PET/CT [171819202122232425].…”

Section: Main Bodymentioning

confidence: 99%

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection

Krimphove

Theißen

Cole

et al. 2020

World J Mens Health

View full text Add to dashboard Cite

Up to 50% of prostate cancer (PCa) patients experience recurrence or disease persistence following local therapy with curative intent. Certainly, some of these men are candidates for adjuvant or salvage local surgical or radiation therapy (RT) approaches including stereotactic/hypo fractionated radiotherapy, salvage lymphadenectomy or prostatectomy [1-3]. However, this clinical decision is typically based in the absence of

show abstract

“…Gallium-68 ( 68 Ga) and Fluorine-18 ( 18 F)-labeled PSMA tracers are highly effective and show high detection rates, especially in PC patients with biochemical recurrence [ 12 , 13 , 14 ]. Due to its high sensitivity, PSMA-PET/CT helps to stratify patients in primary staging of PC for surgery or for systemic treatment by exclusion or detection of metastases [ 15 , 16 ]. Therefore, PSMA-PET/CT has become the most important imaging modality, especially for staging and restaging of PC.…”

Section: Introductionmentioning

confidence: 99%

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy

Moazemi

Khurshid²,

Erle

et al. 2020

Diagnostics

View full text Add to dashboard Cite

Gallium-68 prostate-specific membrane antigen positron emission tomography (68Ga-PSMA-PET) is a highly sensitive method to detect prostate cancer (PC) metastases. Visual discrimination between malignant and physiologic/unspecific tracer accumulation by a nuclear medicine (NM) specialist is essential for image interpretation. In the future, automated machine learning (ML)-based tools will assist physicians in image analysis. The aim of this work was to develop a tool for analysis of 68Ga-PSMA-PET images and to compare its efficacy to that of human readers. Five different ML methods were compared and tested on multiple positron emission tomography/computed tomography (PET/CT) data-sets. Forty textural features extracted from both PET- and low-dose CT data were analyzed. In total, 2419 hotspots from 72 patients were included. Comparing results from human readers to those of ML-based analyses, up to 98% area under the curve (AUC), 94% sensitivity (SE), and 89% specificity (SP) were achieved. Interestingly, textural features assessed in native low-dose CT increased the accuracy significantly. Thus, ML based on 68Ga-PSMA-PET/CT radiomics features can classify hotspots with high precision, comparable to that of experienced NM physicians. Additionally, the superiority of multimodal ML-based analysis considering all PET and low-dose CT features was shown. Morphological features seemed to be of special additional importance even though they were extracted from native low-dose CTs.

show abstract

Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study

Cited by 23 publications

References 14 publications

Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature

Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy

Contact Info

Product

Resources

About